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ABSTRAK 
PENGENALAN 
Glaukoma boleh dikelaskan kepada dua kumpulan utama mengikut struktur sudut;  glaukoma 
sudut terbuka dan glaukoma sudut tertutup. Seterusnya, glaukoma sudut terbuka dan tertutup 
ini boleh dispesifikasikan lagi sama ada jenis primer atau sekunder. Glaukoma sudut terbuka 
primer merupakan jenis glaukoma yang paling lazim. Glaukoma sudut tertutup primer 
menunjukkan prevalens yang agak tinggi di Asia Tenggara dan boleh menyebabkan kebutaan. 
 
Faktor pertumbuhan transformasi beta (TGF- β) mengawal penghasilan dan pembezaan sel, 
perkembangan embrio, penyembuhan luka, dan angiogenesis. Faktor pertumbuhan vascular 
endotelial (VEGF) adalah peptida perangsang yang dihasilkan oleh sel-sel untuk merangsang  
vaskulogenesis dan angiogenesis. Dalam proses penyembuhan luka, terdapat interaksi 
kompleks antara mediator-mediator yang terdiri daripada faktor pertumbuhan, sitokin dan 
kemokin. Pada masa ini, banyak kajian dijalankan untuk mengkaji penglibatan faktor-faktor  
pertumbuhan TGF- β dan VEGF dalam proses penyembuhan luka selepas pembedahan 
glaukoma dan juga sebagai faktor dalam patogenesis glaukoma primer. 
 
OBJEKTIF 
Kajian ini adalah bagi membandingkan tahap faktor-faktor  pertumbuhan TGF-β dan  VEGF 
dalam cecair akueus pesakit glaukoma primer dan kawalan. 
 
 
KAEDAH KAJIAN 
Satu kajian rentas telah dijalankan di antara November 2013 sehingga Februari  2017 di 
Hospital Universiti Sains Malaysia. Secara keseluruhan, 63 mata daripada 63 pesakit yang 
menjalani pembedahan katarak atau pembedahan primer  trabekulektomi  dimasukkan ke 
dalam kajian ini.  
 
Pengambilan pesakit dibahagikan kepada dua kumpulan iaitu glaukoma primer (POAG dan 
PACG) dan kawalan. Sampel cecair akueus secara prospektif dikumpulkan pada awal 
pembedahan daripada 32 mata yang terdiri daripada kumpulan glaukoma primer (16 POAG 
dan 16 PACG) dan juga dari 31 mata kawalan yang menjalani pembedahan katarak dan 
trabekulektomi primer. Kepekatan tahap TGF-β dan VEGF diukur dengan menggunakan 
ujian esei imunoserapan berkaitan enzim (ELISA). 
 
KEPUTUSAN 
Kepekatan median TGF-β dalam cecair akueus mata dengan POAG adalah 2432.50  ± 
3233.57 pg / ml, 1787.40 ± 1650.37 pg / ml dalam PACG dan 1571.40 ±  409.20 pg/ml dalam 
kawalan. Tahap median TGF-β dapat  diperhatikan jauh lebih tinggi dalam kedua-dua 
kumpulan  glaukoma primer  (POAG dan PACG) berbanding dengan kawalan (POAG, p = 
0.004 dan PACG, p = 0.015). Tetapi tidak terdapat perbezaan yang signifikan di antara 
pesakit POAG dan pesakit PACG (p = 0.300). 
 
Tidak terdapat perbezaan yang signifikan dalam tahap median VEGF di antara kedua-dua 
kumpulan glaukoma primer berbanding dengan kumpulan kawalan (p = 0.085), atau pesakit 
POAG dan pesakit PACG (p = 0.043). Kepekatan median VEGF dalam cecair akueus mata 
POAG adalah 518.58 ± 542.61 pg / ml, 307.69 ± 194.39 pg / ml dalam PACG dan 330.20 ± 
202.40 pg / ml dalam kawalan. 
 
KESIMPULAN 
Tahap TGF-β dalam cecair akueus adalah jauh lebih tinggi di dalam mata glaukoma primer 
berbanding dengan kawalan. TGF-β dalam cecair akueus berkemungkinan tinggi memainkan 
peranan dalam patogenesis POAG dan PACG. Tahap VEGF dalam cecair akueus tidak 
berbeza dengan ketara antara kedua-dua mata dalam glaukoma primer berbanding dengan 
kawalan, atau antara mata dengan POAG dan PACG. 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
INTRODUCTION 
Glaucoma can be classified into two main groups according to the angle structure; closed 
angle glaucoma and open angle glaucoma. Open and closed angle glaucoma can further be 
classified into primary or secondary glaucoma. Primary open angle glaucoma (POAG) is the 
most common type of glaucoma. Primary angle closure glaucoma (PACG) has been noted to 
have a relatively high prevalence in Southeast Asia, and to be a leading cause of blindness in 
this region. 
 
Transforming growth factor (TGF- β) regulates the proliferation and differentiation of cells, 
embryonic development, wound healing, and angiogenesis. Vascular growth endothelial 
factor (VEGF) is a signaling peptide produced by cells to stimulate both vasculogenesis and 
angiogenesis. In the process of wound healing, there is a complex interplay of mediators 
comprised of growth factors, cytokines and chemokines. Understanding the role of growth 
factors such as TGF-β and VEGF in the ocular wound healing cascade may increase the 
success rate of glaucoma filtering surgery and knowledge on pathogenesis of primary 
glaucoma. 
 
OBJECTIVE 
To compare the transforming growth factor- beta (TGF-β) and vascular growth endothelial 
factor (VEGF) level in aqueous humor of primary glaucoma patients and controls. 
 
 
METHODOLOGY 
This prospective cross-sectional study was conducted between November 2013 and February 
2017 at Hospital Universiti Sains Malaysia. In total, 63 eyes of 63 patients undergoing 
cataract surgery or primary augmented trabeculectomy surgery were included in this study.  
 
Recruited subjects were classified into primary glaucoma (POAG and PACG) group and 
control group. Aqueous humor samples were prospectively collected at the beginning of 
surgery from 32 eyes with primary glaucoma (16 POAG and 16 PACG) and from 31 control 
eyes that underwent cataract operation and primary augmented trabeculectomy. The 
concentration of TGF-β and VEGF levels was measured by using enzyme-linked 
immunosorbent assay test (ELISA). 
 
RESULTS 
The median concentration (interquertile range (IQR)  of TGF-β in the aqueous humor of eyes 
with POAG was 2432.50 ± 3233.57  pg/ml, 1787.40 ± 1650.37 pg/ml in PACG and 1571.40 ±  
409.20 pg/ml in controls. Median levels of TGF-β were observed to be significantly higher in 
the POAG group and PACG group compared to controls (p = 0.004 and p = 0.015). However 
there was no significant difference between POAG and PACG patients (p = 0.300). 
 
There was also no significant differences in median levels of VEGF between patients with 
primary glaucoma compared to controls (p =0.085), or between POAG and PACG patients 
(p= 0.043). The median concentration of VEGF  in the aqueous humor of eyes with POAG 
was 518.58 ± 542.61 pg/ml, 307.69 ± 194.39 pg/ml in PACG and 330.20 ± 202.40 pg/ml in 
controls. 
 
CONCLUSION 
The aqueous humor TGF-β level was significantly higher in eyes with primary glaucoma 
compared to control. TGF-β in the aqueous humor may play a role in the pathogenesis of  
POAG and PACG. The aqueous humor VEGF level did not differ significantly between eyes 
with primary glaucoma compared to controls, and between eyes with POAG and PACG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
1.1    Primary glaucoma 
Glaucoma is an optic neuropathy usually associated with typical visual field defects (Prum et 
al., 2016). It may be classified into two main groups; closed angle glaucoma and open angle 
glaucoma. Open and closed angle glaucoma is further classified as primary or secondary 
glaucoma. 
 
Primary open angle glaucoma (POAG) is defined as characteristic glaucomatous optic nerve 
damage in an open angle eye with no identifying pathology, with elevated intraocular pressure 
(Ophthalmology, February 2016). The pathogenesis of POAG includes microcirculatory 
deficiency at the optic nerve head, or extracellular matrix factors (ECM)(Kountouras et al., 
2004; Kwon et al., 2009). These factors may play a combined role (Ray and Mookherjee, 
2009). 
 
Primary angle closure glaucoma (PACG) is characterized as chronic, progressive visual field 
loss and optic nerve cupping, often associated with an elevated IOP due to the presence of 
iridotrabecular contact (ITC) by gonioscopy, which can either be appositional or synechial, in 
the absence of underlying secondary ocular disease (European Glaucoma Society, 2014). The 
rise in IOP is due to poor aqueous outflow through the trabecular meshwork leading to a 
build-up in aqueous within the eye, hence increased in IOP (Niwas et al., 2016). 
 
 
 
1.2    Prevalence of Primary glaucoma 
POAG and primary angle closure glaucoma (PACG) are the commonest type of 
glaucoma. WHO estimated the number of people worldwide affected by glaucoma to 
be about 20 million in 1993 (Thylefors and Negrel, 1994). Out of these, POAG is 
responsible for 3.0 million global blindness and PACG is responsible for 2.0 million 
blindness worldwide.  
 
            1.2.1    Prevalence of Primary Open Angle Glaucoma. 
 After cataracts, glaucoma is the second leading cause of blindness in the world (Kingman, 
2004). Open-angle glaucoma is the most common type of glaucoma among populations of 
European or African descent, whereas angle-closure glaucoma is more common among 
populations of Asian descent (Kingman, 2004; Tham et al., 2014). Worldwide in 2015, there 
were an estimated 57.5 million people with open-angle glaucoma, and this number is 
projected to increase to 65.5 million by 2020 (Kapetanakis et al., 2016). It is estimated that 
there are 2.8 million people with open-angle glaucoma in the United States (US) (Quigley and 
Broman, 2006), and that the number will increase to 3.4 million in 2020 (Friedman et al., 
2004). 
 
 
 
 
 1.2.2    Prevalence of Primary Angle Closure Glaucoma 
Angle-closure glaucoma is more prevalent in populations of Asian descent, whereas open-
angle glaucoma is more common in populations of European or African descent (Tham et al., 
2014). Because PACG appears to be more visually damaging, the risk of blindness associated 
with PACG is higher than for POAG (Foster and Johnson, 2001). Foster and Johnson have 
suggested that PACG will probably account for more than 90% of the bilateral glaucoma 
blindness in China (Foster and Johnson, 2001). There is limited data on the incidence of new 
cases of glaucoma in Asia. In Singapore, the incidence of acute symptomatic angle closure 
was highest in Chinese people (12.2/100 000 per year), followed by Malays (6.0/100 000 per 
year) and Indians (6.3/100 000 per year) (Seah et al., 1997; Wong et al., 2000). 
 
 1.3    Pathogenesis of primary glaucoma 
The development of glaucomatous optic neuropathy likely results from a variety of factors. 
Elevated lOP plays a major role in the development of glaucomatous optic neuropathy in most 
individuals and is considered the most significant risk factor. In general, two hypotheses have 
emerged to explain the development of glaucomatous optic neuropathy, the mechanical and 
ischemic theories (Flammer et al., 2002; Flammer and Mozaffarieh, 2007). Both mechanisms 
might lead to a reduction in axoplasmic flow, interference with the delivery of nutrients or 
removal of metabolic products, deprivation of neuronal growth factors, oxidative injury and 
the initiation of immune-mediated damage. Active investigations continue to examine the 
potential role in glaucomatous optic neuropathy of processes such as excitotoxicity (Casson, 
2006), apoptosis, neurotrophin deprivation, ischemia, and autoimmunity. 
 
             1.3.1    Mechanical theory 
The mechanical theory stresses the importance of direct compression of the axonal fibers and 
support structures of the anterior optic nerve, with distortion of the lamina cribrosa plates and 
interruption of axoplasmic flow, resulting in the death of the retinal ganglion cells (Ernest, 
1975; Flammer and Mozaffarieh, 2007). 
 
             1.3.2    Non mechanical theory 
The ischemic theory focuses on the potential development of intraneural ischemia resulting 
from decreased optic nerve perfusion. This perfusion may result from the stress of lOP on the 
blood supply to the nerve or from processes intrinsic to the optic nerve. Disturbance of 
vascular autoregulation may contribute to decreased perfusion and thus to nerve 
damage(Flammer et al., 2002). The optic nerve vessels normally increase or decrease their 
tone to maintain a constant blood flow independent of IOP and blood pressure variations 
(Flammer and Mozaffarieh, 2007). A disturbance in vascular autoregulation may result in 
decreased optic nerve blood flow from increased lOP. Alternatively, changes in systemic 
hemodynamics may result in perfusion deficits, even at normal lOP. Such hypothetical 
derangement could be related to abnormal vessels or to circulating vasoactive substances. 
 
 1.4    Treatment modalities of primary glaucoma 
             1.4.1   Medication 
The goal of currently available glaucoma therapy is to preserve visual function by lowering 
IOP to a level that is likely to prevent further optic nerve damage. The treatment regimen 
chosen should achieve this goal with the lowest risk, fewest adverse effects, and the least 
amount of disruption to the patient’s life, taking into account the cost of treatment. Although 
the goal of treatment is to prevent vision loss, current treatments are aimed at lowering IOP 
and, in the short term, the efficacy of treatment is gauged according to the IOP level. The 
concept of target pressure was introduced because some patients require lower IOP levels than 
do others to stabilize their glaucoma.  
 
In general, the patients who require lower target pressures are those with more advanced optic 
neuropathy, although patients who develop optic nerve damage in the presence of IOP levels 
that are never elevated also require low target levels. Despite the significance of the concept 
of target pressure, it is important not to set a rigid target pressure for the individual patient, as 
there is no evidence base for doing so. The range should be individualized for the patient, 
based on the following: IOP level at which damage is thought to have occurred, severity of 
the damage, life expectancy of the patient, and associated risk factors. The more advanced the 
disease on initial presentation, the lower the target pressure required for preventing further 
progression in the average patient. Once the optic nerve is damaged, it can incur additional 
damage more easily. Once the target pressure range has been determined, the clinician must 
decide how to achieve this goal, medically or surgically. Regardless of which is chosen, the 
anticipated benefits of any therapeutic regimen should justify the risks, and regimens 
associated with substantial adverse effects should be reserved for patients with a high 
probability of progressive vision loss.  
  
 
 
             1.4.2   Laser 
Laser iridotomy is indicated for primary angle closure (PAC) and primary angle-closure 
glaucoma (PACG). Laser iridotomy involves the creation of a hole in the peripheral iris by 
laser (Ritch, 1983; Ritch et al., 1989). The hole provides an alternative pathway for aqueous 
to flow from the posterior chamber into the anterior chamber, bypassing the pupil. Therefore, 
iridotomy eliminates pupillary block and prevents forward bowing of the iris as a result of the 
pressure difference between the two chambers. Iridotomy opens those areas of the angle not 
involved by PAS and prevents further synechial closure. 
 
Argon laser trabeculoplasty (ALT) has been reported to be a reasonably successful treatment 
modality (Wishart et al., 1987; Shirakashi et al., 1989). Selective laser trabeculoplasty (SLT) 
delivers laser energy to pigmented cells in the trabecular meshwork avoiding thermal damage 
to adjacent cells. In a multicenter prospective study on PACG eyes with high IOP despite 
iridotomy but with at least 90° of gonioscopically visible pigmented trabecular meshwork, it 
has shown 20% or more IOP reduction in 54% of eyes at 6 months. The authors suggested 
selective laser trabeculoplasty to be a safe and effective method of reducing IOP in PACG in 
which there is a sufficient extent of visible trabecular meshwork (Ho et al., 2009). If the 
pressure remains uncontrolled and glaucomatous damage develops, filtration surgery is 
indicated.  
 
 
 
 
             1.4.3   Surgery 
Surgical treatment for glaucoma is usually undertaken when medical therapy is not 
appropriate, not tolerated, not effective, or not properly utilized by a particular patient and 
the glaucoma remains uncontrolled with either documented progressive damage or a very 
high risk of further damage. Surgery is usually the primary approach for both congenital 
glaucoma and pupillary block glaucoma. In patients with primary open-angle glaucoma 
(POAG), surgery has traditionally been considered when medical therapy has failed.  
 
Early studies of trabeculectomy as initial therapy for glaucoma suggested that trabeculectomy 
might offer better lOP control, reduction in the number of patient visits to the doctor and 
possibly better visual field preservation. The results of the Collaborative Initial Glaucoma 
Treatment Study (CIGTS) confirmed that initial surgical therapy achieves better lOP control 
than does initial medical therapy (Musch et al., 1999). However, this finding did not translate 
to better visual field stabilization in the average subject because those who received initial 
surgical treatment had a higher risk of cataract in the longer term. In both groups, there was a 
low incidence of visual field progression. Based on this study and current practice. most 
clinicians defer incisional surgery until after an attempt is made to treat with medical therapy 
(Musch et al., 1999). 
 
Trabeculectomy is effective for PACG (Sihota et al., 2004; Tham et al., 2006). 
Trabeculectomy has been shown to have an overall success rate of 68% in controlling IOP. 
However, compared to primary open-angle glaucoma (POAG), any aqueous-draining 
procedure in an eye with a shallow anterior chamber and a chronic closed angle poses the risk 
of further shallowing the anterior chamber or precipitating malignant glaucoma. 
Trabeculectomy in PACG is associated with a higher risk of filtration failure, shallow anterior 
chamber, and malignant glaucoma/aqueous misdirection. As the incidence of PACG increases 
with age, many patients with PACG have co-existing cataract. Trabeculectomy increases the 
rate of cataract progression, and a significant proportion of patients will soon need cataract 
extraction after trabeculectomy. 
 
 1.5    Factors affecting the outcome of glaucoma filtering surgery 
Successful glaucoma filtering surgery is characterized by the passage of aqueous humour 
from the anterior chamber to the subconjunctival space, which results in the formation of a 
filtering bleb. Aqueous in the subconjunctival space may then exit by multiple pathways. Bleb 
failure most often results from fibroblast proliferation and subconjunctival fibrosis. Factors 
associated with an increased risk of bleb failure include youth, aphakia, active anterior 
segment neovascularization, inflammation, previously failed glaucoma filtering surgery, and, 
possibly, race (Skuta and Parrish, 1987). 
 
1.6 Pathophysiology of wound healing in trabeculectomy 
Scarring at the tenon and episcleral level is the main cause of trabeculectomy failure (Skuta, 
1987). Glaucoma surgery is different from other types of surgery which complete healing of 
tissue desirable outcome.  
 
Healing of surgical skin wounds is often considered the prototype repair process that involves 
both replacement and regeneration (Figure 1.1) (Lama and Fechtner, 2003). During 
trabeculectomy, incision is making at conjunctiva and sclera. The initial processes involved in 
healing are inflammation and coagulation, leading to a cascade of biological events including 
cellular, hormonal, and growth factor release. These ultimately lead to repair and scar tissue 
formation. With injury to vascular tissue, leakage of plasma proteins and blood cells occurs. 
Clotting factor activation leads to conversion of fibrinogen to fibrin. Platelet aggregate on 
occurs at the site of endothelial cell damage, which exposes subepithelial collagen. 
 
TGF-β release induces mesenchymal cell and fibroblast activation leading them to 
subsequently reenter the cell cycle, migrate and undergo transformation into myofibroblasts. 
These transformed cells elaborate a host of mediators which degrade the ECM and 
components that frequently fail to restore its original organization. ECM remodeling is 
attributable to excessive accumulation of matrix components consisting of an interlocking 
meshwork of collagen with other ECM components such as proteoglycans and 
glycosaminoglycans (GAGs), which are one of its side chain constituents. Characteristic of 
this remodeling process is tissue granulation accompanied by inflammatory cell influx, 
neovascularization and altered vascular permeability. 
 
Subsequently, the differentiated myofibroblasts transform the secreted  ECM into an actin-
based component which creates stronger scar tissue (Desmouliere et al, 1995). Finally, the 
blood vessels retract over time and fibroblast largely dissapear as the the tissue is remodeled 
to form a dense collagenous subconjunctival scar. 
 
Desjardins et al described three clinicohistopthologic phases of wound healing. In the first six 
days after surgery (early healing), fibroblasts had begun to proliferate along the walls of the 
opening. During the intermediate healing phase (days 7-9), continued proliferation and 
migration of fibroblasts, which were presumably derived from the adjacent episclera and 
subconjunctival tissue, were observed. In the late healing phase (days l0-14), were completely 
closed by granulation tissue.  
 
 
 
 Figure 1.1: Flow chart of the wound healing pathway 
 
 
 
1.7    Human aqueous humour 
Human aqueous humour is a complex mixture of electrolytes, organic solutes, growth factors, 
cytokines, and additional proteins that provide the metabolic requirements to the avascular 
tissues of the anterior segment (Freddo et al., 1990; Barsotti et al., 1992; Freddo, 1993; To et 
al., 2002). It fills both the anterior and the posterior chambers of the eye, which is located in 
the space between the lens and the retina, also known as the posterior cavity or vitreous 
chamber (Figure 1.2).  It is produced from the nonpigmented ciliary body epithelium through 
active transport of ions and solutes and secreted into the posterior chamber (Murray and 
Bartels, 1993; To et al., 2002; Fitt and Gonzalez, 2006). From the posterior chamber, aqueous 
flows between the lens and iris into the anterior chamber.  
 
Human aqueous humour exits the anterior chamber via the trabecular meshwork or 
Schlemm’s canal (conventional outflow pathway) and through the ciliary muscle bundles into 
the supraciliary and suprachoroidal spaces (uveoscleral pathway) (Figure 1.3). A balance 
between the production and the drainage of human aqueous humour is important for 
maintaining the normal physiological intraocular pressure that is essential to maintaining the 
optical and refractive properties of the eye (Mark, 2010). 
 
The protein component of human aqueous humour is minimal, containing between 120 and 
500 ng/μL of protein (Tripathi et al., 1989). The proteins in human aqueous humour are 
thought to arise from plasma as the result of filtration through fenestrated capillaries of the 
ciliary body stroma via the iris root (Freddo, 1993). However, human aqueous humour is not a 
simple diffusate of plasma, since it has both qualitative and quantitative differences in protein 
and ion content in comparison with plasma (Kinsey, 1951; Tripathi et al., 1989). Furthermore, 
proteins in human aqueous humour  that are secreted from the anterior segment tissues may 
have a significant role in the pathogenesisof various eye diseases (Klenkler and Sheardown, 
2004). 
 
A number of growth factors and their associated receptors, including epidermal growth factor, 
transforming growth factor-β, keratinocyte growth factor, hepatocyte growth factor, fibroblast 
growth factor and platelet-derived growth factor have been detected in the human aqueous 
humour (Klenkler and Sheardown, 2004). On binding to cellular receptors, these factors 
activate signalling cascades, which regulate functions including mitosis, differentiation, 
motility and apoptosis. Production of growth factors by corneal cells and their presence in the 
aqueous humour is essential for maintenance and renewal of normal tissue in the anterior eye 
and the prevention of undesirable immune or angiogenic reactions (Klenkler and Sheardown, 
2004).  
 
Growth factors also play a vital role in corneal wound healing, mediating the proliferation of 
epithelial and stromal tissue and affecting the remodelling of the extracellular matrix (ECM) 
(Klenkler and Sheardown, 2004). These functions depend on a complex interplay between 
growth factors of different types, the ECM, and regulatory mechanisms of the affected cells. 
Imbalances may lead to deficient wound healing and various ocular pathologies, including 
edema, neovascularization and glaucoma. 
 
 
 
  
 
 
 
Figure 1.2 : Position of aqueous humour in eyeball 
 
 
 
 
 
  
 
 
 
 
Figure 1.3 : Pathway of aqueous humour (please refer to the arrow) 
 
 
 
 
 
 1.8   Transforming growth factor-beta (TGF-β) 
             1.8.1    TGF-beta in human aqueous humour 
Transforming growth factor-beta (TGF-β) is a member of a family of dimeric polypeptide 
growth factors. TGF- β regulates the proliferation and differentiation of cells, embryonic 
development, wound healing, and angiogenesis (Blobe et al., 2000). There are three isoforms 
of TGF- β: TGF-β1, TGF- β2, and TGF- β3 that have been found in humans (Roberts and 
Sporn, 1988).   
 
             1.8.2    Factor affecting the TGF-beta in human aqueous humour 
Several studies have demonstrated an elevation of TGF-β level in human aqueous humour 
(Jampel et al., 1990; Tovar et al., 2014). Common causes of elevated TGF- β level in human 
aqueous humour include primary glaucoma (Inatani et al., 2001; Ochiai and Ochiai, 2002), 
diabetic eyes (Ochiai and Ochiai, 2002; Min et al., 2006), secondary open angle glaucoma 
complicated with uveitis (Min et al., 2006), high myopia (Zhu et al., 2016) and 
pseudoexfoliation syndrome (Kara et al., 2014). 
 
             1.8.3    TGF-beta level and primary glaucoma 
TGF-β has been implicated in the pathogenesis of primary glaucoma (Tamm and Fuchshofer, 
2007; Fuchshofer and Tamm, 2012). The role of TGF-β in the pathogenesis of POAG has 
been explained by its induction of extracellular matrix (ECM) expression in trabecular 
meshwork (TM) cells and optic nerve head astrocytes. Increased ECM in the TM causes 
increased resistance to aqueous humour outflow, causing higher intraocular pressure (IOP). 
Concurrently, mechanical deformation of optic nerve head axons due to the increased ECM 
may impair axonal transport, which is worsened by the increased IOP. This raised IOP itself 
has been hypothesized to induce further expression of activated TGF-β in trabecular 
meshwork cells and optic nerve head astrocytes, thus propagating a vicious cycle (Tamm and 
Fuchshofer, 2007; Fuchshofer and Tamm, 2012).   
 
 1.9   Vascular endothelial growth factor (VEGF) 
Growth factors are a broad category of endogenous molecules that promote cell proliferation 
or differentiation. These factors include vascular endothelial growth factor (VEGF), fibroblast 
growth factor and transcription factors such as hypoxia inducible factor (Unger et al., 1994; 
Vincent et al., 2000; Samani et al., 2007). VEGF is a signaling peptide produced by cells to 
stimulate both vasculogenesis and angiogenesis. 
 
             1.9.1    VEGF in human aqueous humour 
VEGF, which stimulates the growth of vascular endothelial cells and increases vascular 
permeability, is significantly increased in human eyes with glaucoma (Hu et al., 2002). 
Increased levels of VEGF mRNA and protein are stimulated by hypoxia and ischemia (Aiello 
et al., 1995; Kuroki et al., 1996). The expression of VEGF is potentiated in response to 
hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF induces endothelial 
cell proliferation, promotes cell migration, and inhibits apoptosis (Neufeld et al., 1999). 
 
 
             1.9.2    Factor affecting the VEGF in human aqueous humour 
Ocular VEGF levels are elevated in diseases such as rubeotic glaucoma (Sone et al., 1996), 
uveitic eyes, acute primary angle-closure eyes (Huang et al., 2016), type 2 diabetes, 
proliferative diabetic retinopathy , diabetic macular edema (Costagliola et al., 2013) and 
choroidal neovascularisation (Tong et al., 2006). Van Bergen et al showed VEGF can cause 
the scarring and failure of filtering surgery (Van Bergen et al., 2011). Another study by Li et 
al showed that antiVEGF used in filtering surgery can reduce scarring (Li et al., 2009) . 
 
             1.9.3    VEGF level and primary glaucoma 
Growth factors identified in aqueous humour of eyes with primary glaucoma include VEGF 
(Hu et al., 2002), transforming growth factor-beta (Inatani et al., 2001), fibronectin 
(Babizhayev and Brodskaya, 1989), transferrin (Tripathi et al., 1992) and CD44s (Knepper et 
al., 2002). 
 
 1.10    Enzyme-linked  immunosorbent assays (ELISAs) 
             1.10.1   Principle of ELISA 
ELISA combine the specificity of antibodies with the sensitivity of simple enzyme assays, by 
using antibodies or antigens coupled to an easily-assayed enzyme. ELISA can provide a 
useful measurement of antigen or antibody concentration. The ELISA can be used to detect 
the presence of antigens that are recognized by an antibody or it can be used to test for 
antibodies that recognize an antigen. 
 
A general principle of ELISA is a five-step procedure ( Figure 1.4 & Figure 1.5). An anti-
human TGF-β or VEGF  coating antibody is adsorbed onto microwells (coat the microtiter 
plate wells with antigen). A biotin-conjugated anti-human TGF-β or VEGF  antibody is added 
and binds to human TGF-β or VEGF  captured by the first antibody (block all unbound sites 
to prevent false positive results). Following incubation unbound biotin conjugated anti-human 
TGF-β or VEGF  antibody is removed during a wash step (secondary antibody conjugated to 
an enzyme). Streptavidin- HRP is added and binds to the biotin conjugated anti-human TGF-β 
or VEGF    antibody. Following incubation unbound Streptavidin-HRP is removed during a 
wash step, and substrate solution reactive with HRP is added to the wells. A coloured product 
is formed in proportion to the amount of human TGF-β or VEGF  present in the sample or 
standard (positive reaction). The reaction is terminated by addition of acid and absorbance is 
measured at 450 nm. A standard curve is prepared from 7 human TGF-β or VEGF  standard 
dilutions and human TGF-β or VEGF sample concentration determined. 
 
Compared to other immunoassay methods, there are many advantages of ELISA. ELISA tests 
are more accurate. They are considered highly sensitive, specific and compare favorably with 
other methods used to detect substances in the body, such as radioimmune assay  tests 
(Mossmann et al.,1989). ELISA possesses the added advantages of not needing radioisotopes 
(radioactive substances) or a costly radiation counter (a radiation-counting apparatus). 
 
The high sensitivity of ELISA, comes from the enzyme as a reporting group. As is known to 
all, the enzyme is an organic catalyst, a small amount of which could induce a large span of 
catalytic reactions to produce observable chromogenic reaction phenomenon. Therefore, this 
system is often taken as the amplification system of enzyme. By ELISA, a tracer of the 
antigen or antibody is achieved in the cell or subcellular level, also, antigen or antibody 
quantification can be done in the microgram or even nanogram levels. 
 
Specificity of ELISA is because of the selectivity of the antibody or antigen. Actually, the 
binding of antigen or antibody only occurs in  the epitope of an antigen or antigen-binding site 
of an antibody. Since, there is a complementary relationship between epitope and antigen-
binding site both in chemical structure and spatial configuration, the reaction between antigen 
and antibody shows a strong specifity. These advantages of ELISA make it an useful 
biotechnical tool with many appllicaitons, either in scientific research or clinical diagnosis of 
diseases or conditions. 
 
A major limitation of testing aqueous humor is that only small sample volumes (typically 50 
to 150 μL of fluid) can be obtained from human eyes; these amounts are barely sufficient to 
test a few cytokines using ELISA  techniques. Multiplex bead immunoassays  is another test 
which allow for simultaneous detection of multiple cytokines in small volume clinical 
samples (Takai et al., 2012). 
 
 
 Figure 1.4 Principle of ELISA test for VEGF and TGF 
 Figure 1.5 Principle of ELISA test for VEGF and TGF 
 
 
 
 
 
 
 
 
 
 1.11   Rationale of the study 
TGF-β and VEGF are among the markers that being investigated as susceptibility markers 
and markers to determine the success of glaucoma surgery (Reichel et al., 1996, Cordeiro et 
al., 2000, Park et al., 2013). In the process of wound healing, there is a complex interplay of 
mediators comprising of growth factors, cytokines and chemokines which also include TGF-β 
and VEGF. Based on the conjunctival impression cytology technique, TGF-β has been found 
to be significant higher in both POAG and PACG patients compared to controls in Asian 
patients (Ng et al., 2015). Several studies have shown that the inhibition of VEGF results in 
reduction of scar formation at the trabeculectomy bleb and improves the success of glaucoma 
surgery (Li et al., 2009, Van et al., 2011). TGF-β and VEGF is found in aqueous humour and 
may also contribute to both the pathogenesis of glaucoma and the outcome of glaucoma 
surgery particularly in our population. There were very limited published data on the level of 
TGF- β and VEGF in aqueous humour of glaucoma patients in Asian region. This study may 
improve our understanding of the pathogenesis of primary glaucoma and also factors 
contribute to the outcome of glaucoma filtering surgery in this region.  
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